VIGILANCIA DE LA RESISTENCIA DE STAPHYLOCOCCUS AUREUS  A LA OXACILINA-VANCONICINA Y PATRONES DE CORRESISTENCIA

REFERENCIAS BIBLIOGRÁFICAS

1. Andrews JAsh by J,Jevons.Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and jannuary 1997. j Antimicrob Chemother 1999; 43: 689-698.

2. Antony S.j., Díaz-Vásquez E.,Stratton C. Clinical experience with linezolid in the treatment of resistant gram-positive infections. Journal of the Medical Association. 200 1; 93: 386-391.
3. Barber M. Methicillin resistant staphylococci. j Clin Pathol 1961; 14: 385-393.

4. Bierbaum G, Fuchs K, LenzW, Szekat C, Sahl HG. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur j Clin Microbiol Infect Dis 1999; 18: 691-696.

5. Boyce JM. Methicillin-resistant Staphylococcus aureus: detection, epidemiology, and control meausures.Infect Dis Clin North Am. 1989; 3:901-913.

6. Brun Buisson C. Les Staphylococcus aureus r6sistant a la m6thicilline: evolution et epidemiologie, impact clinique, proyention. Pathol Biol 1998; 46: 227-234.

7. Cáceres U, Zamora R Osorio M. Sensibilidad y resistencia antibiótica al Staphylococcus aureus en el HCFAP VII Congreso Peruano de Enfermedades Infecciosas y Tropicales. Lima-Perú. 1999

8. Centers for Disease Control and Prevention. Staphylococcus aureus resisntant to vancomycin-United States, 2002. MMWR 2002; 5 1:565-567.

9. Centers for Disease Control and Prevention. Staphylococcus aureus with reduce susceptibility to vancomycin-United States, MMWR 1997; 46: 765-766.

10. Chesneau O, Morvan A, El Solh. Enquete d' une technique de detection des souches de S. aureus resistentes a la Vancomycine (53/C9) 18e Réunion Interdisciplinaires de Chimiothérapie Anti-infectieuse, Paris 1998.

11. Collignon P. Increased incidence of methicillin-resistant strains of Staphylococcus aureus in the community.] Infect Dis 1999; 179: 1592.

12. Soussy CJ, Carret G, Cavallo JD. Comité de I'Antibiogramme. Communiqué 2001. Societé Francaise de Microbiologie. France.

13. Diekema Dj, Haller MA, Schmitz Fj and the SENTRY Participans Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and theWestern Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2): S114-S132.

14. El Solh N. Le point sur la resistance aux antibiotiques des staphylocoques. Antibiotiques 2000; 2: 52-63.

15. French GL, Cheng AF, Ling jM. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990; IS: 117-125.

16. Gaynes RRCuIver DH, Horan TC.Trends in methicillin-resistant Staphy)ococcus aureus in United States hospitals. Infect Dis Clin Pract 1993; 2:452-455.

17. Geisel R, Schmitz F-J,Thomas L. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. j Antimicrob Chernother 1999; 43:846-848.

18. Goldstein FW, Courvalin F.Determination de la concentration minimale inhibitrice et de la concentration minimale bactericide en milieu solicle. In: Courvalin R Drugeon H, Flandrois JP, Goldstein FW Bactericidie. Asapect theoriques et therapeutiques. Maloine. Paris 1998.

19. Grosserode MH,Wenzel RPThe continuing importance of staphylococci as major hospital pathogens. J. Hosp Infect. 1991; 19 (suppl.B): 3-17.

20. Hanaki H,Kuwuharaarai K,Boylevavra SActivated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.J Antimicrob Chernother 1998; 42:199-209.

21. Hiramatsu K, Aritaka N, Hanaki H. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-73.

22. Hiramatsu K,Hanaki H,InoTYabuta K,OguriTTenover FC.Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility Antimicrob Chernother 1997; 40:135-6.

23. Hiramatsu K.Vancomycin resistance in staphylococci. Drug Resist Updates 1998;1:135-150.

24. Iglesias D, Cornelo M, León M, Vizcarra C, Macedo M, Luque E. Evolución del Patron de sensibilidad bacteriana entre pacientes hospitalizados del HNSA. 1995-1998.VII Congreso Peruano de Enfermedades Infecciosas y Tropicales. Lima, Peru. 1999

25. Johnson ARWoodford N,George RC. Resistance tovancomycin and teicoplanin: an emerging clinical problem. Clin Microb Rev 1990; 3: 280-91.

26 Ledercq R, Derlot E,Weber M, Duval J, Courvalin P. Transferable vancomycin and teicoplanin in Enterococccus faeci um.Antimicrob Agents Chernother. 1989; 33: 10-5.

27. Levy S. Multidrug resistance a sign of the times. IN Engl J Med 1998; 338: 1376-8.

28. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339:520-532.

29. Marchese A, Balistreri G, Tonoli E, Debbia A, Shito GC. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus isolate in a large Italian hospital. j Clin Microbiol 2000; 38: 866-9.

30. May J, Shanonn K, KingA. Glycopepticle tolerance in Staphylococcus aureus.J. Antimicrob Chernother 1998;42: 189-197.

31. Medina C, Matos E, Alvarez cano j, Tarazona A, Huaroto L. Resistencia antibiótica en cepas de estafilococos en el Hospital Nacional 2 de Mayo. VII Congreso Peruano de Enfermedades Infecciosas y Tropicales. Lima-Peru. 1999

32 National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999.Am J Infect Control 1999; 27:520-32.

33. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chernother 1999; 44:Topic A 19-23.

34. Noble WC Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72: 195-8.

35. Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. NCCLS. M 100-S II Vol. 21 No. 1. January 2001.

36. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F First clinical isolate of van comyc in intermediate Staphylococcus aureus in a French hospital. Lancet 1998;3SI:1212.

37. Protocolo: Estudio de prevalencia de infecciones intrahospitalarias. Documento Técnico (OGE-RENACE/Vig. Hosp. DT 001-99 V-I) Oficina General de Epidemiología. Ministerio de Salud.

38. Scott F.Vancomycin-intermediate and Resistant Staphylococcus aureus:What the Infectious Disease Specialist needs to know. Clin Infect Dis 2001; 32: 108-15.

39. Sieradzki K, Roberts RB, Haber SWThe development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.New England J Med 1999; 340; 5 17-23.

40. Smith TI, Pearson ML, Wilcox. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.

41. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus Vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.

42. Townsend DE,Ashdown N,Bolton S, Bradley J, Duckworth G,Moorhouse EC. The international spread of methicillin-resistant Staphylococcus aureus Hosp Infect 1987; 9:60-71.

43. Turnidge J, Grayson ML. Optimun treatment of staphylococcal infections. Drugs 1993;45:353-66.

44. Velásquez J, Lizaraso F, Casas J, Larrea H. León H, Ale M, Mestanza L. Epiderniologie et resistance aux antibiotiques des bacteries responsables des pneumopathies nosocomiales dans un CHU de Lima-Perou (POS-01).Journées Nationales d'Infectiologie. Lyon.France 2000.

45. Velásquez j, Lizaraso F Goldstein F, Sánchez L.,Wong W, Larrea H., Hernández R. Aislamiento y caracterización de 2 cepas de Enterococcus spp resistentes a la Vancomicina en el Hospital Arzobispo Loayza. VII Congreso Peruano de Enfermedades Infecciosas y Tropicales. Lima-Perú.

46. Velásquez, Lizaraso F, Zetola N, Pamo O, Sánchez L.,Wong W, Hernández R. Vigilancia de la resistencia de Enterococcus sp a la Vancomicina y evaluación in vitro de nuevas alternativas terapéuticas. Rev Soc Per Med Intern 2002; 15: 66-72.

47. Velásquez J, Sacsaquispe R. Antibiograma de Staphylococcus spp. In: Manual de procedimientos para la prueba de sensibilidad antimicrobiana por el método de disco difusión. Serie de Normas Técnicas. Instituto Nacional de Salud.2002; 20:22.

48. Velásquez J, Zetola N, Lizaraso F, Conroy L, Mestanza L Ventilator-associated Pneumonia: Microbiology and sensitivity patterns in a Hospital from Lima, Peru. (41-004) 10th International Congress on Infectious Diseases. Singapore 2002.

49. Vincent JL, Bihari DJ, Suter PM, Bruining HA,White J, Nicolas-Chanoin MH. The prevalence of nosocomial infections in intensive care units in Europe. Results of the European Prevalence in Intensive Care (EPIC) Study. EPIC international Advisory Committee. JAMA 1995; 274:639-44.

50. Voss A, Milatovic Dwallrauch-Schwarz C, Rosdahl VT, Braveny 1. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13:50-5.


Regresar

Volúmenes anteriores